CYP2J2 Gene Plays A Crucial Role in Drug Metabolism (G1573)

Target Name: CYP2J2

NCBI ID: G1573

CYP2J2

CYP2J2 Gene Plays A Crucial Role in Drug Metabolism

CYP2J2 (microsomal monoxygenase), a gene located on chromosome 11, is a protein that plays a crucial role in the metabolism of many drugs, including several commonly prescribed medications. Its function in the body is to metabolize the active ingredients of these drugs, breaking them down into less potent forms that can be excreted from the body.

CYP2J2 is a member of the cytochrome P450 (CYP) enzyme family, which is responsible for the metabolism of a wide variety of drugs, including drugs used to treat a variety of conditions such as heart disease, diabetes, and cancer. CYP2J2 is a monooxygenase , which means it produces one molecule of reactive oxygen (O2) from each oxygen atom in a molecule.

CYP2J2 is expressed in the liver, and its function is to metabolize the active ingredients of drugs by breaking them down into less potent forms that can be excreted from the body. It is widely used in drug discovery and development as a potential drug target or biomarker.

One of the main roles of CYP2J2 is to metabolize the active ingredients of drugs that are metabolized by the liver. Many drugs that are used to treat a variety of conditions are metabolized by the liver, and CYP2J2 is responsible for breaking them down into less potent forms that can be excreted from the body. For example, the drug torsemide, which is used to treat hypertension, is metabolized by CYP2J2 and broken down into its less potent form, which is excreted from the body.

CYP2J2 also plays a role in the metabolism of some drugs that are used to treat psychiatric and neurological disorders. For example, the drug Risperidone, which is used to treat schizophrenia and bipolar disorder, is metabolized by CYP2J2 and broken down into its less potent form , which is excreted from the body.

In addition to its role in drug metabolism, CYP2J2 is also involved in the regulation of cellular processes in the body. For example, it is involved in the production of reactive oxygen, which is an oxygen molecule formed by combining a molecular oxygen atom with a carbonyl group, It can produce free radicals to a variety of molecules within cells, thereby causing damage to cells. Under the action of free radicals, the structure of various biomolecules and organelles in cells changes, causing cell damage.

Variations in the CYP2J2 gene are closely related to drug metabolism and pharmacology research. For example, variations in the CYP2J2 gene may lead to changes in drug metabolism, thereby affecting drug efficacy and toxicity. In addition, mutations in the CYP2J2 gene may also affect the distribution and excretion of drugs in the body, thereby affecting the bioavailability and clearance rate of drugs.

In recent years, mutations in the CYP2J2 gene have received increasing attention. With the development of high-throughput sequencing technology, scientists have been able to accurately detect and analyze the CYP2J2 gene, thus providing a large amount of data for drug metabolism and pharmacology research. In addition, research on drug targets based on the CYP2J2 gene has also made certain progress. These studies provide an important theoretical basis for further exploring the potential of the CYP2J2 gene in drug discovery and development.

Variations in the CYP2J2 gene are closely related to drug metabolism and pharmacology research. Accurate detection and analysis of the CYP2J2 gene can provide a large amount of data for drug metabolism and pharmacology research, thereby providing an important theoretical basis for drug discovery and development.

Protein Name: Cytochrome P450 Family 2 Subfamily J Member 2

Functions: A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) in the cardiovascular system (PubMed:8631948, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:8631948, PubMed:19965576). Catalyzes the epoxidation of double bonds of PUFA (PubMed:8631948, PubMed:19965576). Converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EpETrE), likely playing a major role in the epoxidation of endogenous cardiac arachidonic acid pools (PubMed:8631948). In endothelial cells, participates in eicosanoids metabolism by converting hydroperoxide species into hydroxy epoxy metabolites. In combination with 15-lipoxygenase metabolizes arachidonic acid and converts hydroperoxyicosatetraenoates (HpETEs) into hydroxy epoxy eicosatrienoates (HEETs), which are precursors of vasodilatory trihydroxyicosatrienoic acids (THETAs). This hydroperoxide isomerase activity is NADPH- and O2-independent (PubMed:19737933). Catalyzes the monooxygenation of a various xenobiotics, such as danazol, amiodarone, terfenadine, astemizole, thioridazine, tamoxifen, cyclosporin A and nabumetone (PubMed:19923256). Catalyzes hydroxylation of the anthelmintics albendazole and fenbendazole (PubMed:23959307). Catalyzes the sulfoxidation of fenbedazole (PubMed:19923256)

The "CYP2J2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2J2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets